Welcome to our dedicated page for Y-Mabs Therapeutics SEC filings (Ticker: YMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering if DANYELZA sales are accelerating, or how much cash Y-mAbs has left for its SADA PRIT trials? Biotech filings can bury answers inside pages of risk factors, clinical data tables, and licensing fine print. Stock Titan surfaces what matters immediately.
Our AI reads every 10-K, 10-Q, 8-K, and effective immediately shows you:
- Real-time alerts for Y-mAbs Form 4 insider transactions—spot executive stock moves before the market reacts.
- Concise explanations of each Y-mAbs quarterly earnings report 10-Q filing, including R&D spend and DANYELZA revenue trends.
- Clinical milestone tracking from 8-K material events explained—know when pivotal trial data or FDA feedback hits EDGAR.
If you have ever searched “Y-mAbs SEC filings explained simply” or “understanding Y-mAbs SEC documents with AI,” this page delivers. Stock Titan’s models translate technical jargon into clear takeaways: cash runway, royalty obligations, manufacturing agreements, and pipeline readouts. Use our side-by-side viewer to compare segments across years, export charts, or drill down to Y-mAbs executive stock transactions Form 4.
Whether you need a Y-mAbs annual report 10-K simplified for deep due diligence, a quick look at Y-mAbs proxy statement executive compensation, or an alert on the next Y-mAbs earnings report filing analysis, every document appears here within seconds of hitting EDGAR—already summarized by AI, already linked to the numbers you care about.
Transaction overview: Y-mAbs Therapeutics, Inc. entered into a Merger Agreement dated August 4, 2025 with Perseus BidCo US, Inc. (Parent), Yosemite Merger Sub, Inc. (Purchaser) and Stark International Lux. Purchaser will commence a cash Tender Offer of $8.60 per Share for all outstanding common stock, without interest and subject to applicable withholding taxes. If successful, the Tender Offer will be followed by a merger under Section 251(h) of the Delaware General Corporation Law, with the Company surviving the Merger.
Communications included: This Schedule 14D-9 consists of communications dated August 5, 2025, incorporated as Exhibits 99.1–99.6: a joint press release, an employee email, an investor/analyst letter, a patient and advocacy organization letter, a vendor/supplier letter, and a LinkedIn post.
FAQ
What is the current stock price of Y-Mabs Therapeutics (YMAB)?
What is the market cap of Y-Mabs Therapeutics (YMAB)?
